

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Malaria	<i>Plasmodium falciparum</i> multidrug resistance protein 1 (PfMDR1)	<i>In vitro</i> and cell culture studies identified a PfMDR1-targeting compound, ACT-213615, that could help treat malaria. In biochemical studies with <i>P. falciparum</i> cell lysates, ACT-213615 bound directly to PfMDR1. In <i>P. falciparum</i> cultures, ACT-213615 decreased proliferation at all asexual stages of the parasite cell cycle compared with an inactive control compound. Next steps could include optimizing the lead compound and testing it in models for malarial infection. Actelion Ltd. has an undisclosed molecule in Phase I testing for malaria.	Patented by Actelion; available for licensing	Brunner, R. <i>et al. J. Biol. Chem.</i> ; published online June 10, 2013; doi:10.1074/jbc.M113.453159 Contact: Christoph Binkert, Actelion Ltd., Allschwil, Switzerland e-mail: christoph.binkert@ext.actelion.com
		SciBX 6(29); doi:10.1038/scibx.2013.763 Published online Aug. 1, 2013		